In the realm of pharmaceuticals, the interest in therapeutic oligonucleotides is burgeoning, prompting a crucial shift towards embracing sustainability within the oligonucleotide manufacturing landscape. The current practices in oligonucleotide production are laden with inefficiencies, utilizing copious amounts of hazardous reagents, solvents, and energy-intensive processes throughout synthesis, purification, and isolation stages. Recognizing this unsustainable trend, the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (GCIPR) identified the urgent need for greener processes in oligonucleotide manufacturing. As a response, collaborative efforts have been initiated to enhance sustainability in oligonucleotide production involving academia, contract research organizations, and the pharmaceutical industry.
Oligonucleotides, unique therapeutic molecules composed of short modified DNA strands, hold immense potential in treating a wide array of diseases through their distinct ability to target specific genetic sequences. These molecules can induce degradation or splice-switching in RNA molecules, crucial in combating genetic diseases or viral infections. Moreover, oligonucleotides can form intricate three-dimensional structures called aptamers, enabling high-specificity binding to target molecules. Augmenting the in vivo properties of oligonucleotides with structural modifications enhances their stability, cellular uptake, and binding affinity, paving the way for innovative therapeutic interventions.
The manufacturing process of single-stranded therapeutic oligonucleotides encompasses synthesis, purification, and isolation stages. Synthesis primarily follows the solid-supported phosphoramidite method, a well-established technique involving sequential chemical reactions on a solid support matrix. The subsequent purification step typically employs preparative chromatography, with reversed-phase and anion exchange chromatography being common methods. Post-purification, desalting of the oligonucleotide solution is crucial to remove buffer components and concentrate the product, with techniques like precipitation and tangential flow filtration (TFF) being employed.
Assessing the sustainability of the oligonucleotide manufacturing process against the 12 Principles of Green Chemistry and the Process Mass Intensity (PMI) metric reveals key areas for improvement. The 12 Principles highlight waste generation, poor atom economy, and excessive reagent usage as significant challenges in the current process. Calculating PMI metrics for various oligonucleotide processes sheds light on material efficiency, showcasing the need for optimization to align with sustainable manufacturing practices.
Efforts to enhance sustainability in oligonucleotide synthesis have made notable progress over the years, focusing on waste reduction, solvent recovery, and reagent reuse. Implementing innovative approaches like solvent recycling, dynamic axial compression columns, and alternative protecting groups can significantly reduce waste generation and enhance process sustainability. Furthermore, advancements in chromatographic techniques, such as Hydrophobic Interaction Chromatography (HIC) as a green alternative to Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), demonstrate promising avenues for sustainable purification practices.
Looking towards the future, long-term sustainability goals in oligonucleotide manufacturing could involve compound design optimization, alternative synthesis methods, and novel purification techniques. Strategies like continuous diafiltration, spray-drying as an energy-efficient alternative to lyophilization, and exploring solutions that eliminate the drying step entirely hold promise in enhancing the sustainability of oligonucleotide manufacturing processes. By innovating across compound design, synthesis, purification, and isolation stages, the pharmaceutical industry can pave the way for a more sustainable future in oligonucleotide production.
In conclusion, the journey towards sustainable oligonucleotide manufacturing presents a realm of opportunities for innovation and collaboration across academia, industry, and research organizations. By embracing green chemistry principles, optimizing material efficiency, and leveraging novel technologies, the pharmaceutical landscape can revolutionize oligonucleotide production towards a greener, more sustainable future.
Takeaways:
– Oligonucleotide manufacturing faces sustainability challenges due to wasteful practices and energy-intensive processes.
– Collaboration between academia, industry, and research organizations is crucial for enhancing sustainability in oligonucleotide production.
– Compound design optimization, alternative synthesis methods, and innovative purification techniques are key to long-term sustainability goals in oligonucleotide manufacturing.
Tags: formulation, drug delivery, lyophilization, process development, chromatography, downstream, filtration, clinical trials, analytical chemistry
Read more on pmc.ncbi.nlm.nih.gov